---
source_path: S24022-PDF-ENG.md
pages: n/a-n/a
chunk_id: 0e7724c753e833848d660a0411a7c12a5c432158
title: S24022-PDF-ENG
---
## smaller biotech ﬁrms, patient advocacy groups, hospitals, insurers, and

manufacturing partners) to accelerate drug discovery and development.

It continually invests in and tunes the model as the company grows. For

example, as Vertex expanded globally and became more decentralized,

it created new ways to promote innovation, such as tournaments,

training programs, and facilitated lectures by leading scientists. To

improve its breakthrough cystic-ﬁbrosis treatments, it works with

health care providers to optimize care pathways from hospital centers

into patients’ homes, creating better patient experiences and outcomes.

Copyright © 2024 Harvard Business School Publishing. All rights reserved.

6

This document is authorized for use only by Matt O'Donnell (matthew.od11@gmail.com). Copying or posting is an infringement of copyright. Please contact customerservice@harvardbusiness.org or 800-988-0886 for additional copies.
